Consolidated balance sheet
|
in CHF 1 000 |
|
Notes |
|
30.06.2023 |
|
31.12.2022 |
|
Current assets |
|
|
|
|
|
|
|
Cash and cash equivalents |
|
|
|
900 |
|
1 948 |
|
Receivables from brokers |
|
|
|
4 602 |
|
– |
|
Securities |
|
3 |
|
2 572 727 |
|
3 051 349 |
|
Other assets |
|
|
|
232 |
|
92 |
|
|
|
|
|
2 578 461 |
|
3 053 389 |
|
Total assets |
|
|
|
2 578 461 |
|
3 053 389 |
|
|
|
|
|
|
|
|
|
Current liabilities |
|
|
|
|
|
|
|
Short-term borrowings from banks |
|
4 |
|
308 500 |
|
363 000 |
|
Payables to brokers |
|
|
|
4 478 |
|
– |
|
Other short-term liabilities |
|
|
|
2 916 |
|
4 143 |
|
Tax liabilities |
|
|
|
76 |
|
111 |
|
|
|
|
|
315 970 |
|
367 254 |
|
Total liabilities |
|
|
|
315 970 |
|
367 254 |
|
|
|
|
|
|
|
|
|
Shareholders' equity |
|
|
|
|
|
|
|
Share capital |
|
5 |
|
11 080 |
|
11 080 |
|
Treasury shares |
|
5 |
|
(36 508) |
|
(36 508) |
|
Retained earnings |
|
|
|
2 287 919 |
|
2 711 563 |
|
|
|
|
|
2 262 491 |
|
2 686 135 |
|
Total liabilities and shareholders' equity |
|
|
|
2 578 461 |
|
3 053 389 |
|
|
|
|
|
|
|
|
|
Net asset value per share in CHF |
|
|
|
41.25 |
|
49.00 |
The notes are an integral part of the condensed consolidated interim financial statements.
The condensed consolidated interim financial statements were approved by the Board of Directors of BB Biotech AG on July 18, 2023.